# EDGAR Filing Document

**Accession Number:** 0001137883
**File Stem:** 0001104659-25-065799
**Filing Date:** 2025-7
**Character Count:** 28989
**Document Hash:** d3f4b50f63d8115b4bbf84a343e300b5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-065799.hdr.sgml**: 20250703

**ACCESSION NUMBER**: 0001104659-25-065799

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 4

**FILED AS OF DATE**: 20250703

**DATE AS OF CHANGE**: 20250703

**EFFECTIVENESS DATE**: 20250703

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC.
- **CENTRAL INDEX KEY:** 0001137883
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 207273918
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288520
- **FILM NUMBER:** 251105971

**BUSINESS ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019
- **BUSINESS PHONE:** 201-488-0460

**MAIL ADDRESS:**
- **STREET 1:** 1325 AVENUE OF AMERICAS
- **STREET 2:** 28TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10019

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** BRAINSTORM CELL THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20041122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GOLDEN HAND RESOURCES INC
- **DATE OF NAME CHANGE:** 20030827

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WIZBANG TECHNOLOGIES INC
- **DATE OF NAME CHANGE:** 20010409

**As filed with the Securities and Exchange Commission on July 3, 2025**

**<br> Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

------

**BRAINSTORM CELL THERAPEUTICS INC.**

**(Exact name of registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **20-7273918** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**1325 Avenue of Americas, 28th Floor, New York, NY, 10019** <br> (Address of Principal Executive Offices, Zip Code)

**2014 Stock Incentive Plan**

**2014 Global Share Option Plan**

(Full title of the plan)

**Chaim Lebovits**

**President and Chief Executive Officer**

**Brainstorm Cell Therapeutics Inc.**

**1325 Avenue of Americas, 28th Floor**

**New York, NY 10019**

(Name and address of agent for service)

**(201) 488-0460**

(Telephone number, including area code, of agent for service)

------

***Copies to:***

**Mitchell S. Bloom, Esq.**

**Mayan Katz, Esq.**

**Goodwin Procter LLP**

**100 Northern Ave**

**Boston, Massachusetts 02210**

**(617) 570-1000**

------

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | x | Smaller reporting company | ⌧ |
|  |  | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

**EXPLANATORY NOTE**

Pursuant to General Instruction E to Form S-8, this Registration Statement on Form S-8 (this "Registration Statement") is being filed to register an additional 2,533,333 shares of common stock, par value $0.00005 per share ("Common Stock"), of Brainstorm Cell Therapeutics Inc. (the "Registrant") reserved under the Registrant's 2014 Stock Incentive Plan and the 2014 Global Share Option Plan, each as amended through June 25, 2025 (as amended, collectively, the "2014 Plans"), including (i) additional 533, 333 shares of Common Stock (as adjusted to reflect the reverse stock split effected in October 2024) reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on September 16, 2024, and (ii) additional 2,000,000 shares of Common Stock reserved under the 2014 Plans pursuant to the amendments thereto adopted by the stockholders on June 25, 2025. This Registration Statement registers additional securities of the same class as other securities of the Registrant for which the registration statements filed on Form S-8 relating to the 2014 Plans ([File No. 333-198391](https://www.sec.gov/Archives/edgar/data/1137883/000114420414052667/v387660_s8.htm), [File No. 333-213714](https://www.sec.gov/Archives/edgar/data/1137883/000114420416124601/v448950_s8.htm), [File No. 333-228981](https://www.sec.gov/Archives/edgar/data/1137883/000114420418066053/tv508312_s8.htm) and [File No. 333-261598](https://www.sec.gov/Archives/edgar/data/1137883/000110465921148601/tm2134979d1_s8.htm)) of the Registrant are effective. The information contained in the Registrant's registration statements on Form S-8 relating to the 2014 Plans ([File No. 333-198391](https://www.sec.gov/Archives/edgar/data/1137883/000114420414052667/v387660_s8.htm), [File No. 333-213714](https://www.sec.gov/Archives/edgar/data/1137883/000114420416124601/v448950_s8.htm), [File No. 333-228981](https://www.sec.gov/Archives/edgar/data/1137883/000114420418066053/tv508312_s8.htm) and [File No. 333-261598](https://www.sec.gov/Archives/edgar/data/1137883/000110465921148601/tm2134979d1_s8.htm)) is hereby incorporated by reference pursuant to General Instruction E of Form S-8, except with respect to Item 8. Exhibits thereof.

**Part II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8.** **Exhibits.**

The exhibits listed on the Exhibit Index immediately preceding such exhibits are filed as part of this Registration Statement, and the contents of the Exhibit Index are incorporated herein by reference.

**EXHIBIT INDEX** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit <br> Number** | <br>**Exhibit Description** | <br>**Filed<br> Herewith** | **Form** | **SEC File /<br> Registration<br> Number** | **Exhibit** | **Filing Date** |
| [4.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Certificate of Incorporation of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [11/20/2006](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |
| [4.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated September 15, 2014.](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [000-54365](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) | [09/16/2014](https://www.sec.gov/Archives/edgar/data/1137883/000114420414056076/v389167_ex3-1.htm) |
| [4.3](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc. dated August 31, 2015.](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) |  | [8-K](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [001-366641](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [3.1](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) | [09/04/2015](http://www.sec.gov/Archives/edgar/data/1137883/000114420415053827/v419788_ex3-1.htm) |
| [4.4](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 16, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [001-366641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex3-1.htm) |
| [4.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [Certificate of Amendment of Certificate of Incorporation of Brainstorm Cell Therapeutics Inc., dated September 30, 2024.](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [001-366641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) | [10/01/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_ex3-1.htm) |
| [4.6](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [ByLaws of Brainstorm Cell Therapeutics Inc.](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [Appendix C](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) | [11/20/2006](https://www.sec.gov/Archives/edgar/data/1137883/000114420406048981/v058081def14a.htm) |
| [4.7](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [Amendment No. 1 to ByLaws of Brainstorm Cell Therapeutics Inc., dated as of March 21, 2007.](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) | [03/27/2007](https://www.sec.gov/Archives/edgar/data/1137883/000114420407014718/v069555_ex3-1.txt) |
| [4.8](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [Amendment No. 2 to the Bylaws of Brainstorm Cell Therapeutics Inc., dated as of April 20, 2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [333-61610](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [3.1](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) | [04/21/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925036851/tm2512729d1_ex3-1.htm) |
| [5.1](tm2519000d1_ex5-1.htm) | [Opinion of Goodwin Procter LLP](tm2519000d1_ex5-1.htm) | [X](tm2519000d1_ex5-1.htm) |  |  |  |  |
| [23.1](tm2519000d1_ex5-1.htm) | [Consent of Goodwin Procter LLP (included in opinion of counsel filed as Exhibit 5.1)](tm2519000d1_ex5-1.htm) | [X](tm2519000d1_ex5-1.htm) |  |  |  |  |
| [23.2](tm2519000d1_ex23-2.htm) | [Consent of Brightman Almagor Zohar & Co., a Firm in the Deloitte Global Network.](tm2519000d1_ex23-2.htm) | [X](tm2519000d1_ex23-2.htm) |  |  |  |  |
| [24](#a_001) | [Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement)](#a_001) | [X](#a_001) |  |  |  |  |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| [99.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [000-54365](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) | [08/15/2014](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-1.htm) |
| [99.2](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |  | [Definitive Schedule 14A](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [000-36641](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Appendix A](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [05/11/2016](http://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [99.3](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [Amendment No. 2 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [10.1](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) | [11/30/2018](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-1.htm) |
| [99.4](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Appendix A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [10/01/2020](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [99.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [Amendment No. 4 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [10.5](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-5.htm) |
| [99.6](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [Amendment No. 5 to the Brainstorm Cell Therapeutics Inc. 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [10.6](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) | [06/25/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-6.htm) |
| [99.7](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [000-54365](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [10.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) | [08/15/2014](https://www.sec.gov/Archives/edgar/data/1137883/000114420414050690/v386869_ex10-2.htm) |
| [99.8](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Amendment No. 1 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) | [05/11/2016](https://www.sec.gov/Archives/edgar/data/1137883/000114420416100632/v439388_def14a.htm) |
| [99.9](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [Amendment No. 2 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [10.2](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) | [11/30/2018](https://www.sec.gov/Archives/edgar/data/1137883/000114420418062647/tv508229_ex10-2.htm) |
| [99.10](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Amendment No. 3 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |  | [Definitive Schedule 14A](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [Appendix B](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) | [10/01/2020](https://www.sec.gov/Archives/edgar/data/1137883/000110465920111107/tm2032174d1_def14a.htm) |
| [99.11](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [Amendment No. 4 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [10.10](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) | [09/16/2024](https://www.sec.gov/Archives/edgar/data/1137883/000110465924100239/tm2424130d1_ex10-10.htm) |
| [99.12](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [Amendment No. 5 to Brainstorm Cell Therapeutics Inc. 2014 Global Share Option Plan](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) |  | [8-K](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [000-36641](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [10.12](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) | [06/25/2025](https://www.sec.gov/Archives/edgar/data/1137883/000110465925062595/tm2518995d1_ex10-12.htm) |
| [107](tm2519000d1_ex-filingfees.htm) | [Filing Fee table](tm2519000d1_ex-filingfees.htm) | [X](tm2519000d1_ex-filingfees.htm) |  |  |  |  |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in City of New York, State of New York, on July 3, 2025.

---

| | |
|:---|:---|
| **BRAINSTORM CELL THERAPEUTICS INC.** | **BRAINSTORM CELL THERAPEUTICS INC.** |
| By: | /s/ Chaim Lebovits |
|  | **Chaim Lebovits** |
|  | **President and Chief Executive Officer** |

---

Each person whose signature appears below constitutes and appoints Chaim Lebovits, Uri Yablonka and Alla Patlis, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Chaim Lebovits<br> Chaim Lebovits | President and Chief Executive Officer<br> (Principal Executive Officer) | July 3, 2025 |
| /s/ *Alla Patlis*<br> *Alla Patlis* | Interim Chief Financial Officer<br> (Principal Financial and Accounting Officer) | July 3, 2025 |
| /s/ *Irit Arbel*<br> *Irit Arbel* | Director | July 3, 2025 |
| /s/ *Nir Naor*<br> *Nir Naor* | Director | July 3, 2025 |
| /s/ *Jacob Frenkel*<br> *Jacob Frenkel* | Director | July 3, 2025 |
| /s/ *Anthony Polverino*<br> *Anthony Polverino* | Director | July 3, 2025 |
| /s/ *Uri Yablonka*<br> *Uri Yablonka* | Director | July 3, 2025 |
| /s/ *Menghisteab Bairu*<br> *Menghisteab Bairu* | Director | July 3, 2025 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; /s/ *Stacy Lindborg*<br> *Stacy Lindborg* | Director | July 3, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**

July 3, 2025

Brainstorm Cell Therapeutics Inc.

1325 Avenue of Americas, 28th Floor

New York, NY 10019

Attention: Chief Executive Officer

Re: <u>Securities Being Registered under Registration Statement on Form S-8</u>

We have acted as your counsel in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 2,533,333 shares (the "Shares") of Common Stock, par value $0.00005 per share ("Common Stock"), of Brainstorm Cell Therapeutics Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2014 Stock Incentive Plan and 2014 Global Share Option Plan, each as amended (collectively, the "Plans").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on a certificate of officers of the Company.

For purposes of the opinion set forth below, we have assumed that, at the time Shares are issued, the total number of then unissued Shares, when added to the number of shares of Common Stock issued, subscribed for, or otherwise committed to be issued, does not exceed the number of shares of Common Stock authorized by the Company's certificate of incorporation, as amended.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered against payment therefor in accordance with the terms of the Plans, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 *Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Brainstorm Cell Therapeutics Inc.

July 3, 2025

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in Registration Statement on Form S-8 of our report dated March 31, 2025, relating to the financial statements of Brainstorm Cell Therapeutics Inc. (the "Company") appearing in the Annual Report on Form 10-K of the Company for the year ended December 31, 2024. We also consent to the reference to us under the heading "Experts" in such Registration Statement.

/s/ Brightman Almagor Zohar & Co.

**Brightman Almagor Zohar & Co.**

Certified Public Accountants

A Firm in the Deloitte Global Network

Tel Aviv, Israel

July 3, 2025

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Tables**

<u>Form S-8</u>

(Form Type)

**<u>Brainstorm Cell Therapeutics Inc.</u>**

(Exact name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u>

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| Security<br> Type | Security Class Title | Fee<br> Calculation<br> Rule | Maximum<br> Aggregate<br>Offering Price | Fee Rate | Amount of<br> Registration Fee |
| Equity | Common Stock, $0.00005 par value per share | 457(h)2533333<sup>(2)</sup>$1.06<sup>(3)</sup> | $2685332.98 | 0.00015310 | $411.12 |
| &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | &nbsp;&nbsp;&nbsp;Total Offering Amounts | $2685332.98 |  | $411.12 |
| &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets | &nbsp;&nbsp;&nbsp;Total Fee Offsets |  |  |  |
| &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due | &nbsp;&nbsp;&nbsp;Net Fee Due |  |  | $411.12 |

---

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"),
this Registration Statement on Form S-8 ("Registration Statement") shall also cover any additional shares of common stock,
$0.00005 par value per share (the "Common Stock") of Brainstorm Cell Therapeutics Inc. (the "Registrant") that
become issuable under the Registrant's 2014 Stock Incentive Plan and 2014 Global Share Option Plan, as amended (the "Plans"),
by reason of any stock dividend, stock split, recapitalization or any other similar transactions.

(2) Represents an increase of 2,533,333 shares of Common Stock available for issuance under the Plans.

(3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the
Securities Act, and based on $1.06, the average of the high and low sale prices of the Common Stock as reported on Nasdaq on June 27,
2025 (such date being within five business days of the date that this Registration Statement was filed with the Commission).